Contineum Therapeutics, Inc. 8K

Contineum Therapeutics furnished a July 2026 corporate presentation describing its PIPE-791-led R&D pipeline, partnership and financial runway, including deferral of CTX-343 and Janssen’s control over PIPE-307 development.

Contineum Therapeutics, Inc. furnished a July 2026 corporate overview presentation as Exhibit 99.1 to its Form 8-K, outlining its pipeline and strategy centered on its lead small-molecule candidate PIPE-791, a brain-penetrant LPAR1 antagonist being advanced into a global Phase 2 trial for idiopathic pulmonary fibrosis with projected completion in June 2028, and also being evaluated for chronic pain, while disclosing that it has deferred further development of CTX-343 pending dedicated funding and continues to rely on a global license and development agreement under which Janssen Pharmaceutica NV retains sole discretion over further development of PIPE-307 (JNJ-5120) for major depressive disorder or other indications; the presentation also highlights a projected cash runway through mid-2029, the clinically validated nature of its targets, and key partnership economics with Janssen on PIPE-307, including milestones and tiered royalties.

Filing Facts

CIK

1855175

Ticker

CTNM

Form

8K

Source Type

fda

Accession

0001628280-26-048023

Alert Tier

5